1420006
USP
Levodopa Related Compound B
United States Pharmacopeia (USP) Reference Standard
Sinónimos:
DL-3-O-Methyldopa, 3-Methoxytyrosine
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
C10H13NO4
Número de CAS:
Peso molecular:
211.21
UNSPSC Code:
41116107
NACRES:
NA.24
Productos recomendados
grade
pharmaceutical primary standard
API family
levodopa
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
InChI
1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)
InChI key
PFDUUKDQEHURQC-UHFFFAOYSA-N
¿Está buscando productos similares? Visita Guía de comparación de productos
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
Also, for use with USP monographs such as:
- Carbidopa and Levodopa Orally Disintegrating Tablets
- Levodopa
- Carbidopa and Levodopa Tablets
- Carbidopa and Levodopa Extended-Release Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Related product
Referencia del producto
Descripción
Precios
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Stephanie L Merhar et al.
Pediatrics, 116(5), 1226-1230 (2005-11-03)
Chronic bilirubin encephalopathy, characterized clinically by extrapyramidal movement abnormalities, vertical gaze abnormalities, and hearing loss, results from neuronal injury after marked hyperbilirubinemia in term and preterm infants. In premature infants, bilirubin staining of specific brain structures has been described at
Thomas Müller et al.
Naunyn-Schmiedeberg's archives of pharmacology, 383(6), 627-633 (2011-05-03)
Elevation of plasma total homocysteine concentrations were observed in levodopa/dopa decarboxylase inhibitor (DDI)-treated patients with Parkinson's disease (PD). Degradation of levodopa to 3-O-methyldopa via the enzyme catechol-O-methyltransferase (COMT) is a methyl group demanding reaction. It generates homocysteine from the methyl
Li-Hsuan Wang et al.
Phytotherapy research : PTR, 24(6), 852-858 (2009-11-27)
The impacts of caffeic acid (3,4-dihydroxycinnamic acid, CA) on the pharmacokinetics of levodopa (L-dopa) were studied in rabbits. A single dose of 5/1.25 mg kg(-1) L-dopa/carbidopa was administered alone or was co-administered with three different doses of caffeic acid (2.5
T Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 114(11), 1457-1462 (2007-06-15)
The interval of line tracing performance is more associated to basal ganglia function due to the dependence on bradykinesia and rigidity. The other component of this task, the precision of execution of complex movement sequences, is more related to attention.
Yoritaka Onzawa et al.
Biological & pharmaceutical bulletin, 35(8), 1244-1248 (2012-08-07)
It has been well known that 3-O-methyldopa (3-OMD) is a metabolite of L-3,4-dihydroxyphenylalanine (L-DOPA) formed by catechol O-methyltransferase (COMT), and 3-OMD blood level often reaches higher than physiological level in Parkinson's disease (PD) patients receiving long term L-DOPA therapy. However
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico